Non-Small Cell Lung Cancer — Pemetrexed Plus Cetuximab in Patients With Recurrent Non Small Cell Lung Cancer
Citation(s)
A Phase I-IIa Dose-Ranging Study of Pemetrexed (Alimta) Plus Cetuximab (Erbitux) in Patients With Recurrent Non-Small Cell Lung Cancer (NSCLC): Hoosier Oncology Group LUN04-79